


# RECENT THERAPIES FOR HR+/HER2- BREAST CANCER

with **Kevin Kalinsky** Winship Cancer Institute of Emory University (GA, USA)



 Recent approval for Verzenios<sup>®</sup> (abemaciclib), based on the Monarch-E trial

## Limitations and challenges of current treatments

Identifying whether premenopausal women can replace chemotherapy with ovarian function suppression

## How can the 21-Gene Assay inform treatment sequencing?

 In RxPONDER, postmenopausal women with recurrence score 0–25 do not benefit from chemotherapy



Future predictions for HER-2 breast cancer treatment options

 An increasing role for circulating markers – such as ctDNA

if 1–3 lymph nodes involved

 Premenopausal women with these characteristics, however, benefit from chemotherapy



 As well as exciting endocrine agents, such as oral selective estrogen receptor down regulators

# Interviewee profile

#### Name:

Kevin Kalinsky

### **Affiliation:**

Director of the Glenn Family Breast Center and Director of Breast Medical Oncology at the Winship Cancer Institute of Emory University (GA, USA)



EMORY WINSHIP CANCER INSTITUTE National Cancer Hulture Designated

